Allergic Responses Induced by a Fungal Biopesticide Metarhizium anisopliae and House Dust Mite Are Compared in a Mouse Model by Ward, Marsha D. W. et al.
Hindawi Publishing Corporation
Journal of Toxicology
Volume 2011, Article ID 360805, 13 pages
doi:10.1155/2011/360805
Research Article
AllergicResponsesInducedbyaFungalBiopesticideMetarhizium
anisopliae andHouseDust MiteAreCompared ina Mouse Model
Marsha D. W.Ward, YongJoo Chung,LisaB. Copeland,and Donald L.Doerﬂer
National Health and Environmental Eﬀects Research Laboratory, U.S. Environmental Protection Agency, 109 T. W. Alexander Drive,
MD B105-02, Research Triangle Park, NC 27711, USA
Correspondence should be addressed to Marsha D. W. Ward, ward.marsha@epamail.epa.gov
Received 4 November 2010; Revised 8 March 2011; Accepted 6 April 2011
Academic Editor: Anthony DeCaprio
Copyright © 2011 Marsha D. W. Ward et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Biopesticides can be eﬀective in controlling their target pest. However, research regarding allergenicity and asthma development
is limited. We compared the ability of fungal biopesticide Metarhizium anisopliae (MACA) and house dust mite (HDM) extracts
to induce allergic responses in BALB/c mice. The extracts were administered by intratracheal aspiration at doubling doses (2.5–
80µg protein) 4X over a four-week period. Three days after the last exposure, serum and bronchoalveolar lavage ﬂuid (BALF)
were collected. The extracts’ relative allergenicity was evaluated based on response robustness (lowest signiﬁcant dose response
compared to control (0µg)). MACA induced a more robust serum total IgE response thanHDM. However, in the antigen-speciﬁc
IgE assay, a similar dose of both MACA and HDM was required to achieve the same response level. Our data suggest a threshold
dose of MACA for allergy induction and that M. anisopliae may be similar to HDM in allergy induction potential.
1.Introduction
The toxicity associated with many chemical pesticides has
provided the impetus to develop biological agents, either
native or genetically engineered, for pest control. Although
the microorganisms (bacteria, viruses, and fungi) that have
been identiﬁed or developed for release in the environment
to address problems such as pest control [1–3]c a nb e
eﬀective in controlling their target pest, adverse health
impacts to mammalian species including humans may be a
consequence of exposure to these organisms. Generally, the
research regarding mammalian health impacts has focused
on the potential toxicity and pathogenicity of these agents.
However, research regarding the allergenicity of the agents is
more limited.
Allergy (atopy), a Type I or immediate-type hypersensi-
tivity reaction, is an immune response to otherwise innocu-
ous “nonself” agents (generally proteins) in genetically
predisposed individuals. Although most proteins are capable
of eliciting immune responses, not all proteins are allergens
[4]. Generally, there are no apparent disease symptoms
during allergy induction (sensitization). However, some B
cellsswitchproductionofimmunoglobulin(Ig)isotypefrom
IgM to IgE (or IgG1 in guinea pigs) antibodies. In pre-
viously sensitized individuals, allergen reexposure/challenge
cross-links antigen-speciﬁc mast cell/basophil-bound IgE
antibodies resulting in the immediate release of preformed
mediators (including histamine and prostaglandins). Allergy
symptoms become apparent as these mediators produce
bronchoconstriction, increased vascular permeability, and
inﬂammation. The clinical manifestations of allergy range
from skin rashes and rhinitis to life-threatening asthmatic
and anaphylactic reactions. In the case of asthma, a late-
phase response may also be seen between 2–12 hours
after challenge characterized by mucus hypersecretion,
bronchoconstriction, airway hyperresponsiveness (AHR) to
nonspeciﬁc stimuli, for example, histamine or methacholine
(Mch), and eosinophilic airway inﬂammation.
The incidence of asthma has increased dramatically over
the last several decades in the U.S. and other industrialized
nations, particularly for allergic asthma [5, 6]. This trend has
been noted in both the general population and in occupa-
tionalsettings[7].Itisassumedthatchangesinenvironment,
lifestyle, and/or medical practices have contributed to the2 Journal of Toxicology
increase, as the change is more dramatic than would be
expected for a simple population genetic shift [8, 9]. Allergic
p o t e n t i a li so fp a r t i c u l a rc o n c e rn because, in addition to the
medical and the economic burden on the general population
[10], the percentage of adult asthmatics that are allergic
asthmatics is estimated to range from 50% [11]t o>90%
[12].
Molds/fungi are ubiquitousin the environment and have
been implicated in the etiology of respiratory hypersen-
sitivity diseases such as allergic rhinitis, allergic asthma,
allergic bronchopulmonary mycoses, and hypersensitivity
pneumonitis [13, 14]. In fact, many fungal genera have been
associated with allergic lung disease, but only a few fungi
are well studied and even fewer fungal allergens well char-
acterized. A recent review [15] described epidemiological
evidence of an association between fungal exposure and
asthma severity. Although estimates suggest that 3–10% of
people worldwide have fungal allergies [16], Mari et al.
[17] found that 19.1% of their allergy study population had
positive mold skin prick tests. Another factor that could
be contributing to the increased incidence of asthma is
childhood exposure to molds [18, 19]. There are limited
studies addressing the allergenicity of fungal biopesticides.
Furthermore, it is also important to assess the relative
allergenicity of these agents by comparing responses to those
induced by a well-characterized, indoor allergen such as
house dust mite (HDM).
Metarhizium anisopliae is a fungal biopesticide that has
been used for agricultural pest control for over a century
because of its pathogenicity for a broad range of susceptible
insect hosts. This entomopathogenic Deuteromycetes(Fungi
imperfecti) fungus is a soil borne fungus found worldwide.
M. anisopliae has been investigated as a control for sugarcane
pests [20, 21] as well as other crop pests and ectoparasites
including mites [22–24] and livestock ticks [25]. Currently,
M. anisopliae is used to control insects such as grasshoppers,
termites, and thrips and is licensed in the United States for
indoor use in cockroach control. Additionally, M. anisopliae
has been investigated as a mosquito control to combat
malaria by impregnating mosquito netting with viable
conidia [26, 27]. The conidia are the environmentally stable
portion of the fungal life cycle and a viable reproductive
unit. Furthermore, Dr. Ravichandra Potumarthi reported
at the 2007 International Conference on Bioengineering
and Nanotechnology [28] that his laboratory has used M.
anisopliae inanenergyeﬃcientmethodtoproducebiodiesel.
These studies indicate a potential increase in opportunities
for both indoor residential and occupational exposures to
what is ecologically an outdoor organism.
There is no evidence that M. anisopliae is toxic to
humans or other mammals. However, there are several
case studies documenting infection by M. anisopliae in
immunocompromised [29] and immunocompetent [30]
individuals as well as a case of invasive rhinitis in a cat [31].
Thus suggesting that in some instances humans and other
mammals may be susceptible to M. anisopliae infection.
Previous studies in our laboratory [32, 33]h a v ed e m o n -
strated that multiple respiratory exposures to M. anisopliae
extract can elicit inﬂammatory and respiratory physiological
responses characteristic of human allergic asthma in BALB/c
mice. Furthermore, anecdotal information as well as limited
clinical data has suggested that some individuals exposed
occupationally to M. anisopliae have become sensitized [34].
More recently human sera IgE reactivity with M. anisopliae
hasbeenidentiﬁed.Barbieri etal.[35]demonstrated positive
skin-prick test reactions to M. anisopliae in occupationally
exposed sugarcane workers with allergic asthma and/or
rhinitis. Ward et al. [36] found human serum IgE reactivity
withcatalaseinM.anisopliae extractWesternblots.However,
no IgG reactivity was identiﬁed, suggesting that the IgE
reactivity was the result of cross-reactivity to catalase from
another source. Additionally, Instanes et al. [37]d e m o n -
strated that M.anisopliae mycelia extract contains substances
that have adjuvant activity in a mouse ovalbumin allergy
model. These studies indicate that exposure to M. anisopliae
not only may induce allergic responses but could potentiate
allergic responses to other allergenic agents.
The study goal was to compare the allergic responses
inducedby themold extract, M.anisopliae (MACA),to those
of house dust mite extract (HDM), a known inducer of
allergic asthma [38], in an allergic asthma mouse model.
2.Materialsand Methods
2.1. Animals. Fifty-day-old female BALB/c mice (Charles
River, Raleigh, NC) were group-housed in polycarbonate
cages with hardwood chip bedding in an environmen-
tally controlled, American Association for Accreditation of
Laboratory Animal Care-accredited vivarium. Mice were
maintained on a 12-h light/dark cycle and allowed access to
food (Purina Rodent Lab Chow, St. Louis, MO) and water
ad libitum. Mice were allowed to acclimate one week prior
to the start of the experiment. All animal procedures were
reviewed and approved by the Institutional Animal Care and
Use Committee of NHEERL, US EPA.
2.2. Fungal Antigen Preparation. M. anisopliae strain 1080
was obtained from USDA-ARS Entomopathogenic Fungus
Collection (Ithaca, NY). The fungus was grown as described
in Ward et al. [39]. Brieﬂy, mycelium (hyphae growth) was
grown at 27◦C for 72h in Sabouraud’s maltose broth with
aeration (150rpm). Subsequently, the mycelium was washed
twice with saline to remove media contaminants and air-
dried overnight in a biosafety cabinet. Fungal cultures for
conidiadevelopmentwere incubatedat 27◦ConSabouraud’s
maltose agar for 2 to 3 weeks. These components were
extracted by grinding with a sterile mortar and pestle
for approximately 5min followed by Polytron (Kinematica,
Basel, Switzerland) homogenization for 2min in a total of
15 volumes (by weight) of Hanks’ balanced salt solution
(HBSS, Gibco BRL, Life Technologies Inc., Rockville, MD)
+0.05% (v/v) Tween 80 (Fisher Scientiﬁc, Pittsburgh, PA).
The resulting suspension was stirred overnight at 4◦C,
and then centrifuged at 12,500 ×gf o r1 ha t4 ◦C. The
supernatant was decanted, and then adjusted to pH 6.0
with HCl. Additionally, a deprivation medium (absence
of readily available nitrogen and carbon) of unpuriﬁed
chitin (Sigma Chemical Co., Grand Island, NY) at 3% inJournal of Toxicology 3
water was inoculated with M. anisopliae and incubated at
27◦C for 72h with aeration (150rpm) for higher yields
of inducible proteases and chitinases [40, 41]. The ﬁltrate
was retained following passage through Whatman no. 1
ﬁlter paper. Each ﬁltrate was concentrated with a stirred-
cell concentrator (Amicon, Inc., Beverly, MA) using YM3
membranes (molecular weight > 3000Da cutoﬀ)a n dﬁ l t e r
sterilized with a 0.2µm syringe ﬁlter. Each individual crude
antigen extract was assayed for total protein concentration
using a Pierce BCA protein assay kit (Pierce, Rockford,
IL) with bovine serum albumin as a standard according to
manufacturer’s procedures. The three component extracts
were combined in equal protein amounts to provide M.
anisopliae crude antigen (MACA) extract. Endotoxin level of
the extract was measured using a Limulus amoebocyte lysate
test kit (BioWhittaker, Walkersville, MD); the level at the
highest dose (80µg protein) was 0.28 endotoxin unit (EU).
Lyophilized whole body extracts of house dust mites
(HDM) Dermatophagoides farinae and D. pteronyssinus
purchased from Greer Laboratories (Lenoir, NC), were
rehydrated in HBSS to 3mg/mL, mixed equally and stored
in aliquots at –80◦C until use. Endotoxin level of the highest
dose (80µg protein) was 0.27EU.
2.3. Experimental Design. For each protein extract, 6 mice
were exposed to 2.5, 5, 10, 20, 40, or 80µgo fe x t r a c ti n
HBSS(total volume of 50µl) by intratracheal aspiration (IA)
4 times over a four-week period, as previously described
[32].Additionally,controlmice were exposed toHBSSalone.
Brieﬂy, mice were anaesthetized by inhalation of a mixture
of 3% isoﬂurane and 97% oxygen. Antigen extract was
deposited into the oropharynx, after which mice inhaled
the extract when their noses were gently occluded with a
ﬁngertip. Mice were weighed after each exposure and at
necropsy. The rationale for the exposure protocol (Figure 1)
is based on the immunology paradigm that the primary
immune response is approximately 7–14 days following the
initial exposure (Day 28 to Day 14, see Figure 1)a n d
approximates the sensitizing phase of allergy induction. The
second exposure in our protocol is 14 days (D 14) after
the ﬁrst and thus is on the boundary between sensitization
a n dc h a l l e n g e .H o w e v e r ,t h el a s tt w oe x p o s u r e sa tD7a n d
D 0 are challenge exposures. Serum and bronchoalveolar
lavage ﬂuid (BALF) were collected three days following the
ﬁnal exposure. BALF was assessed for lactate dehydrogenase
(LDH) activity, total protein, total cell, and diﬀerential cell
counts. Serum was assessed for total and mold or dust
mite-speciﬁc IgE. The responses of allergen extract-treated
mice were compared to results obtained from HBSS control
animals.
2.4. Bronchoalveolar Lavage (BAL) and Blood Collection.
Blood and BALF samples were collected as previously de-
scribed in [39]. Brieﬂy, mice were anaesthetized with sodium
pentobarbital and blood samples were collected by cardiac
puncture. The blood was allowed to clot for 1-2h at room
temperature prior to serum separation by centrifugation,
and the serum was stored at –80◦C until analysis. The lungs
were lavaged twice with 1mL aliquots of HBSS, and the
pooled BALF aliquots were stored on ice. The BALF was
centrifuged at 100 ×gf o r1 5 m i na t4 ◦C. An aliquot of
the supernatant was stored at 4◦C for total protein and
LDH activity assay and the remainder stored at −80◦C. The
cell pellet was resuspended in 1mL of HBSS. Total BALF
cell counts were obtained using a Coulter counter (Coulter
Corp., Miami, FL). Additionally, 100–150µL of resuspended
cells were adhered onto glass slides at 200rpm for 10min
usingaCytospin2centrifuge(ShandonInc.,Pittsburgh,PA).
The BALF cells on glass slides were stained with Wright-
Giemsa (Fisher Scientiﬁc) on a Hema-Tek 2000 slide stainer
(Miles, Inc., Elkhart, IN) and were diﬀerentially counted at
200 cells per slide (one slide per animal).
2.5. Total Protein and Lactate Dehydrogenase (LDH) Assays.
BALF samples were assayed for total protein using Pierce
Coomassie Plus Protein Assay Reagent (Pierce). Concentra-
tions were determined from a standard curve using BSA
standards obtained from Sigma Chemical Co. (St. Louis,
MO). Additionally, the BALF samples were assayed for LDH
activity using a commercially prepared kit and controls from
Sigma Chemical Co. The assays were modiﬁed for use on the
KONELAB30clinical chemistry spectrophotometer analyzer
(Thermo Clinical Labsystems, Espoo, Finland).
2.6. Total IgE ELISA. All reagents and incubations were at
roomtemperature,andallvolumesaddedwere100µLunless
otherwise noted. Total IgE ELISA was performed as previ-
ously described by Ward et al. [39]. Puriﬁed monoclonal
antimouse IgE (PharMingen, San Diego, CA) in phosphate
buﬀered saline (PBS), pH 7.3, was used as the capture
antibody and biotinylated rat antimouse IgE (BD Bio-
sciencePharMingen) asthedetectionantibody. Streptavidin-
conjugated horseradish peroxidase (Zymed, San Francisco,
CA) was the detection enzyme with TMB substrate (DAKO
Corporation,Carpinteria,CA).Opticaldensitywasread ona
Thermomax Plate Reader (Molecular Devices Corp., Menlo
Park, CA) at a wavelength of 650nm. Softmax Pro version
2.6.1 (Molecular Devices Corp.) software was used for data
collection and conversion from optical density to protein
concentrations. The limit of detection for this assay was
6.25ng/mL.
2.7. Antigen-Speciﬁc IgE Assay. A rat basophilic leukemia
(RBL) cell beta-hexosaminidase release assay was performed
as an indirect measure of antigen-speciﬁc IgE in serum. The
procedure is based on the method by Hoﬀmann et al. [42],
with modiﬁcations by D. Leadbeater and D. A. Basketter
(personal communication, Unilever Safety and Environ-
mental Assurance Center, UK). The procedures have been
previously described in Chung et al. [43]. Brieﬂy, 96-well
ﬂat bottom tissue culture plates were seeded with 105 RBL-
2H3 cells (ATCC, Rockville, MD) and incubated for 18hr
at 37◦Ci na5 %C O 2 humidiﬁed incubator. The cells were
passively sensitized with a 1:4 dilution of individual mouse
serum or with normal sera (spontaneous and total release
controls) for 2hr. Cells were then washed with Tyrode’s4 Journal of Toxicology
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Figure 1: Experimental Timeline. Mice were administered MACA, HDM, or HBSS (control group) by intratracheal aspiration (IA) 4 times
overa 4-week period. Allergy sensitizationandchallengephases areindicated. BloodandBALFwere collected 3 daysafter the ﬁnalexposure.
buﬀer followed by the addition of allergen extracts (10µg)
and incubated for 1hr at 37◦Ci na5 %C O 2 humidiﬁed
incubator.Forspontaneousrelease, cellswereincubatedwith
buﬀer alone. Beta-hexosaminidase, the mediator measured,
is a chitinase and chitinases are produced by some fungi.
Therefore an additional control was used to identify extract-
speciﬁc (endogenous) chitinase activity; both MACA and
HDM extracts were added to cells that were not passively
sensitized (no serum). The higher OD for spontaneous
release or extract-speciﬁc release was used to calculate the
% of total mediator release. For total release, cells were
incubated with 1% (v/v) Triton X-100 (Sigma) in Tyrode’s
buﬀer. Subsequently, the beta-hexosaminidase activity was
measured by combining cell culture supernatant and sub-
strate (p-nitrophenyl N-acetyl beta-d-glucosaminide) in a
sterile 96-well plate and incubating the plate for 1hr at
room temperature. The enzyme reaction was stopped by the
addition of 0.2M glycine. Absorbance was measured 30min
later using a SpectraMax 340 PC Plate Reader (Molecular
Devices Corp.) at a wavelength of 405nm and data collected
by Softmax Pro software (version 2.6.1, Molecular Devices
Corp.). Data are presented as percent total release following
subtractionofspontaneousreleaseorextract-speciﬁc activity
if higher. Additionally, the extract dose resulting in 10% of
total release was calculated by interpolation.
% of Total beta-hexosaminidase Release
=
Sample Release OD −

Spontaneous Release OD
or
Extract-Speciﬁc Release OD

Total Release OD − Spontaneous Release OD
× 100.
(1)
Additionally, endogenous chitinase activity was mea-
sured for both HDM and MACA by adding chitinase
s u b s t r a t et o0 ,1 ,5 ,a n d1 0µg/mL of each extract, as well as,
10µg/mL of trypsin and processing as described above.
2.8. Protease Assay. Extracts were analyzed for protease
activity using the EnzChek7Protease Assay Kit (red ﬂuores-
cence) (Molecular Probes, Eugene, OR). Triplicates of ﬁve
concentrations (0–20µg/mL) of the extracts as well as a
trypsin enzyme control were added to the digestion buﬀer
( 2 0 0m MT r i s - H C l ,p H7 . 8 ,c o n taining 2mM sodium azide).
Following the addition of BODIPY7 TR-X labeled casein
substrate in 0.1M sodium bicarbonate, pH 8.3, the samples
were protected from light and incubated for 1hr. Protease-
catalyzed hydrolysis of the substrate and subsequent release
of BODIPY7 TR-X dye-labeled peptides results in increased
ﬂuorescencethat isproportionaltoproteaseactivity. Fluores-
cence of the BODIPY7 TR-X dye was read in a ﬂuorometer
(Spectra Max, Gemini XS, Molecular Devices) using a ﬁlter
withexcitation = 590±10nm,emission = 645±20nm.Data
are reported as percent of trypsin control.
2.9. Statistical Analysis. The data were analyzed in two
stages. First, a two-way analysis of variance (ANOVA) model
was applied to the data, without the control group. This
allows the examination of the main eﬀects, of exposures
(HDM and M. anisopliae) and doses (2.5, 5, 10, 20, 40,
80µg extract protein), and interactive eﬀects. Additionally,
exposure-groups were formed and compared to the control
values, using a Dunnett’s test. This was done to examine
diﬀerences from the control group without reference to the
ANOVA ﬁndings. The level of signiﬁcance was set at 0.05.
Additionally, the estimated dose at which 10% of total
mediator release occurred was calculated for the antigen-
speciﬁcIgE(RBLassay) data.Thiswasaccomplishedthrough
linear interpolation between responses at consecutive doses
bracketing the 10% value. The level of signiﬁcance was set at
0.05.
3.Results
3.1. Change in Body Weight. Although the mice were
weighed after each exposure and at necropsy (3 days after
the 4th exposure) to assess overt toxicity of the extracts,
the percent weight change was calculated based on their
weight after the ﬁrst exposure and at necropsy. Control
mice (HBSS exposures only) increased their body weight
by 13.01% ± 0.99 over the study time course (Figure 2).
The percent weight change for the HDM-exposed mice
was similar to that of the control mice with the lowest
percent weight change being 10.57% ± 1.99 at the 10µg
dose level. MACA-exposed mice tended to have a lower and
dose-dependent percentage of weight change than controls,Journal of Toxicology 5
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Figure 2:% changeinbody weight from ﬁrstexposure to necropsy.
(§) the lowest signiﬁcant dose compared to HBSS (0 dose control),
statistically signiﬁcant diﬀerences (a) between extracts at the same
dose and (b) from all lower doses within treatment.
reaching a signiﬁcant diﬀerence at the 80µgd o s el e v e l
(−1.25%± 3.46).
3.2. Total Protein and Lactate Dehydrogenase (LDH) Levels.
Elevations in BALF total protein are indicative of pulmonary
vascular leakage (pulmonary edema). Mice exposed to 20µg
of MACA or 40µg of HDM showed a signiﬁcant increase
in total protein levels compared to the 0µg dose control
mice (Figure 3(A)). The response to HDM and MACA
extracts displayed a trend toward dose-dependent increases
particularly at high doses. However, mice treated with 20–
80µg of MACA had a signiﬁcant increase in the total protein
level compared to mice exposed to similar doses of HDM.
Elevated LDH activity in BALF is indicative of non-
speciﬁc cellular damage. Mice exposed to 80µgo fM A C A
showed a signiﬁcant increase in LDH activity compared to
the 0µg dose controls and 80µgo fH D M( F i g u r e3(B)).
In this study, HDM-treated mice did not have signiﬁcantly
diﬀerent LDH activity at any dose level.
3.3. BALF Total and Diﬀerential Cell Counts. BALF total and
diﬀerentialcellcountswere assessed to determinetherelative
eﬀect of the extracts in the development of the late-phase
allergic response in this mouse model. BALF total cell counts
were dose dependently increased in HDM- and MACA-
exposed mice (Figure 4(A)). The lowest doses of MACA
and HDM that induced a signiﬁcant increase in total cell
counts compared to 0µg dose controls were 5µg( 1 2 .97 ±
2.15×104 cells/mL) and 10µg( 1 4 .28±1.73×104 cells/mL),
respectively.
Both BALF macrophage and lymphocyte counts were
dose dependently increased in HDM-exposed mice across
the dose range. MACA-exposed mice demonstrated dose-
dependent increases in both cell types through the 20µg
dose level, then the responses plateaued at much higher
levels than those of HDM-exposed mice (Figures 4(B) and
4(C)). The lowest doses of MACA and HDM that caused a
signiﬁcant elevation in macrophage counts compared to 0µg
dose controls were 2.5µg( 8 .48 ± 1.80 × 104 cells/mL) and
5µg( 9 .30 ± 1.15 × 104 cells/mL), respectively (Figure 4(B)).
The lowest doses of MACA and HDM that induced a
signiﬁcant increase in lymphocyte counts compared to 0µg
dose controls were 5µg( 1 .30±0.61×104 cells/mL) and 10µg
(1.33+0.21 × 104 cells/mL), respectively (Figure 4(C)).
Dose-dependent increases in BALF neutrophil counts
were observed in HDM- and MACA-treated mice (Fig-
ure 4(D)). The lowest doses of MACA and HDM that caused
a signiﬁcant elevation of neutrophil counts compared to 0µg
dose controls were 10µg (1.16 + 0.38 × 104 cells/mL) and
40µg( 2 .72+ 0.69 × 104 cells/mL), respectively.
Mice exposed to 20–80µgo fM A C As h o w e ds i g n i ﬁ c a n t
increases in total cell, macrophage, and neutrophil cell
counts. A similar pattern of response was demonstrated by
lymphocytecounts;however,atthe80µgdos ethediﬀerences
between the treatments were not signiﬁcant.
Eosinophilic airway inﬂammation is an endpoint charac-
teristic of allergic asthma responses. BALF eosinophil counts
were increased in a dose-dependent matter through the dose
range for HDM and in the lower dose range for MACA. The
lowest dose that induced a signiﬁcant elevation of eosinophil
counts compared to 0µg dose controls was 10µgf o rb o t h
HDM and MACA (Figure 4(E)). HDM-treated mice showed
increasing eosinophil counts to the highest dose (80µg;
33.98 ± 7.61 × 104 c e l l s / m L ) .H o w e v e r ,M A C A - t r e a t e dm i c e
showed a maximum number of eosinophils at 20µg( 2 2 .72±
4.04 × 104 cells/mL) dose. Although the eosinophil numbers
tended to decline with the increase in dose levels, this decline
in MACA-induced eosinophil inﬂux were not statistically
signiﬁcant. There was no statistically signiﬁcant diﬀerences
the eosinophil inﬂux induced by the two extracts except at
the 80µg dose level where HDM-induced eosinophil counts
were signiﬁcantly higher than those for MACA-exposed
mice. Whether the limited weight gain at higher doses is
related to the MACA-induced eosinophil inﬂux decline with
increases in dose is unclear.
In a separate study, mouse BALF was collected 2 days
after the mice received a single 20µgd o s eo fe x t r a c t .
Both HDM and MACA were able to induce a robust in-
ﬂux of neutrophils, as well as, a small but signiﬁcant in-
ﬂux of eosinophils compared to control mouse responses
(Figure 4(F)). However, as expected, there was no signiﬁcant
diﬀerenceintheserumtotalorantigen-speciﬁcIgEresponses
induced by either extract compared to control mice 2 days
after a single extract exposure (data not shown).
3.4. Total and Antigen-Speciﬁc IgE. Elevated IgE levels are
one of the key indicators of atopic status and are frequently
associated with allergic airway disease. BALF total IgE
increased in MACA-treated mice dose dependently. The 20
µg dose was the lowest signiﬁcant dose compared to the6 Journal of Toxicology
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Figure 3: Total protein levels (A), and LDH activity (B) in BALF collected 3 days after the ﬁnal exposure to HDM or MACA. Symbols
indicate (§) the lowest signiﬁcant dose compared to HBSS (0 dose control), statistically signiﬁcant diﬀerences (a) between extracts at the
same dose, (b) from all lower doses within treatment, (c) from 2.5µga n d5µg doses within treatment, (d) signiﬁcantly diﬀerent from 2.5 to
10µg doses within treatment, or (e) signiﬁcantly diﬀerent from 2.5 to 20µg doses within treatment (P<. 05). Error bars represent standard
error of the mean. Control n = 12; HDM and MACA n = 5-6.
0µg control mice (Figure 5(A)). Additionally, MACA in-
duced signiﬁcantly more BALF total IgE than HDM from
across the 20–80µg dose range. HDM-treated mice did not
demonstrate a signiﬁcant increase in BALF total IgE at any
dose.
MACA-treated mice demonstrated dose-dependent
increases in serum total IgE up to the 40µgd o s el e v e l
but tended to decline at the 80µg dose level. Although
HDM-treated mice demonstrated a dose-dependentincrease
in serum total IgE throughout the dose range the magnitude
of the response was signiﬁcantly lower than that induced by
MACA at the 20–80µgd o s e s( F i g u r e5(B)). The lowest dose
of MACA or HDM that induced a signiﬁcant increase in
total IgE compared to 0µg dose controls was 20µga n d4 0µg
of extract, respectively.
Asanindirect measure offunctional antigen-speciﬁc IgE,
the release of the preformed mediator beta-hexosaminidase
was measured using the rat basophil leukemia (RBL) cell
assay. When analyzed across the dose range, it required 20µg
of extract to induce a signiﬁcant increase compared to the
0µg dose control for both MACA and HDM (Figure 5(C)).
To provide a basis for comparing the extracts’ ability to
induce antigen-speciﬁc IgE, the extract dose resulting in
10% of total beta-hexosaminidase release was calculated
(Figure 5(D)). This calculated dose indicated that it required
slightly less HDM extract (13.17µg) to achieve 10% of total
mediator release than MACA (16.16µg).
The mediator beta-hexosaminidase measured in the RBL
assay is a chitinase. Therefore, it was important to determine
if any portion of the mediator release measured in that
assay was due to endogenous levels of chitinase activity
(Figure 5(E)). Both MACA and HDM demonstrated similar
enzymatic activity which increased with the increase in
extract concentration.
3.5. Protease Activity. Fungal extract protease activity can
amplify the inﬂammatory responses of allergic disease
through protease-activated receptors on epithelial cells [44].
The extracts were assayed for proteolytic activity to investi-
gate how diﬀerences might impact extract-induced allergic
responses. HDM protease activity ranged from 1/4t o1 /2
of trypsin proteolytic activity. On the other hand, MACA
proteolyticactivitywasmore than6-foldgreaterthantrypsin
activity for 5–20µg/mL extract concentrations (Figure 6).
4.Discussion
Previous studies in our laboratory [32, 33, 39]h a v ef o u n d
that M. anisopliae extract has the capacity to induce allergic
responses in a mouse model. In the present study, the
relative allergenicity of the biopesticide M. anisopliae was
compared to HDM induced responses based on various
endpoints with an emphasis on those that are characteristic
of human allergic responses, for example, serum total and
antigen-speciﬁc IgE and inﬂammatory cell (neutrophils and
eosinophils) inﬂux into the lungs (summarized in Table 1).
It is of interest that at higher doses (20–80µg), MACA-
treated mice demonstrated a signiﬁcantly higher level of
serum total IgE than the HDM-treated mice displayed.
However, similar doses of each extract were required to
induce the same response level (10% of total mediator
release) for antigen-speciﬁc IgE. We have seen a similar eﬀectJournal of Toxicology 7
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Figure 4: Total cell counts (A) and diﬀerential cell counts (Macrophage(B), Lymphocyte (C), Neutrophil (D), and Eosinophil(E)) in BALF
of HDM- or MACA-exposed mice collected 3 days after the ﬁnal exposure. Control n = 12; HDM and MACA n = 5-6. (F) BALF total and
diﬀerential cell counts 2 days after a single exposure to HBSS or 20µg of either HDM or MACA. Control n = 4; HDM and MACA n = 5.
Symbols indicate (§) the lowest signiﬁcant dose compared to HBSS (0 dose control), statistically signiﬁcant diﬀerences (a) between extracts
at the same dose, (b) from all lower doses within treatment, (c) from 2.5µga n d5µg doses within treatment, (d) signiﬁcantly diﬀerent
from 2.5 to 10µg doses within treatment, (e) signiﬁcantlydiﬀerent from 2.5 to 20µg doses within treatment, (#) signiﬁcantly diﬀerent from
control (P<. 05). Error bars represent standard error of the mean.8 Journal of Toxicology
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Table 1: Summary of endpoints based on the lowest dose that induced a signiﬁcantresponse compared to the 0 µgd o s e a and the magnitude
o ft h er e s p o n s ea tt h a td o s e .
Source Endpoint
Relative potency
Lowest dose for signiﬁcant responsea (response magnitude)
MACA HDM
BALF
Total protein (µg/mL) 20 (222.74 ±53.81)   80 (57.85± 11.69)
LDH activity (U/l) 80 (66.14 ±11.66)   NSb
Total cell count (×104 cells/mL) 5 (12.97 ±2.15) > 10 (14.28±1.73)
Macrophage count (×104 cells/mL) 2.5( 8 .48± 1.80) > 5( 9 .30± 1.15)
Neutrophil count (×104 cells/mL) 10 (1.16+0.38)   40 (2.72+0.69)
Eosinophil count (×104 cells/mL) 10 (3.94 ±1.44) = 10 (2.02± 0.42)
Lymphocyte count (×104 cells/mL) 5 (1.30 ±0.61) > 10 (1.33± 0.21)
Total IgE (ng/mL) 20 (23.21 ±3.30)   NS
Serum
Total IgE (ng/mL) 20 (4056.98 ±564.31) > 40 (1693.79±329.84)
Antigen-speciﬁc Releasec (% Total mediator release) 20 (14.06 ±5.71) ∼ 20 (18.64±5.08)
Antigen-speciﬁc IgEd (µg extract) 16.16 ∼ 13.17
aDose (µg extract) resulting in a signiﬁcant increase over 0µg dose control at P<. 01.
b NS: no signiﬁcant dose compared to 0µg dose control.
c For antigen-speciﬁc IgE, dose comparison was made to the 2.5µgd o s e .
d Calculated dose that would induce suﬃcientantigen-speciﬁc IgE resulting in 10% of total mediator release in RBL assay.
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Figure 6: Extract protease activity compared to trypsin protease
activity control.
in serum total IgE in studies where Stachybotrys chartarum
was compared to HDM except more S. chartarum extract
was required to achieve the same response level in the
antigen-speciﬁc IgE assay [45]. This “by-stander” eﬀect was
demonstrated by Moss [46] who found an IL-4-dependent
elevation of nonspeciﬁc IgE was induced by A. fumigatus in
an allergic bronchopulmonary aspergillosis mouse model.
Although a single exposure to either of these extracts
(20µg) did not induce increases in serum or BALF total
IgE or antigen-speciﬁc/functional IgE (serum), it did result
in a signiﬁcant increase in BALF total and diﬀerential
cells compared to controls (Figure 4(F)) but to varying
degrees. There were a prominent increase in neutrophils
and a small but signiﬁcant increase in eosinophils compared
to the controls. The ability to induce this neutrophilic
response in na¨ ıve individuals could enhance their potential
to induce and/or exacerbate allergic asthma [47, 48]. A
direct comparison ofthe single and multipleexposure results
c a n n o tb em a d es i n c et h e s ew e r ep e r f o r m e di ns e p a r a t e
studies. However, it appears that multiple exposures may
have a damping eﬀect on the neutrophil inﬂux suggesting
the impact on allergy might reside in early exposures but
does not preclude the potential to exacerbate allergic asthma
symptoms.
An unexpected ﬁnding was the decline in percent body
weight change in MACA-exposed mice with the increase in
exposure dose compared to both control and HDM-exposed
mice. The necropsy weight was measured 3 days after dosing;
this could reﬂect a general malaise induced for a short
period following MACA dosing. However, when percent
weight change was calculated using mouse weight at the 4th
exposure (7 days after the previous dose) a similar but less
dramatic pattern of weight change existed (data not shown).
We have also observed a less dramatic decline in percent
body weight with mice exposed to high doses of Stachybotrys
chartarumextract(unpublisheddata).Thesedatasuggestthe
possibility of overt toxicity at higher exposure doses of some
molds and the need for further investigation in the area.
There are a number of factors that might aﬀect the
diﬀerential responses seen between the two extracts studied.
One such factor might be diﬀerences in the quality or
quantity of the “allergens”among the extracts. As was shown
in murine model of allergic asthma, A. fumigatus allergens
diﬀer in their ability to induce IgE, eosinophils, and airway
hyperresponsiveness and can diﬀerentially aﬀect the allergic
asthma pathogenesis [49]. Furthermore, the authors found
that in addition to the allergens, other extract components10 Journal of Toxicology
such as enzymes and toxins contributed to the overall
responses leading to allergic asthma. Althoughallergens have
been identiﬁed in M. anisopliae [35, 36], possible diﬀerences
in allergen quality or quantity among molds have not been
described.
Protease activity has been shown to play a role in
allergic responsiveness [50] possibly by causing epithelialcell
damage [51]or by the ampliﬁcation ofallergic inﬂammatory
responses through protease-activated receptors on epithelial
cells [44]. MACA had signiﬁcantly more protease activity
than the trypsin control or HDM which were similar.
Furthermore, in this study a lower dose of MACA versus
HDM was required to induce a signiﬁcant response increase
compared to control animals. Therefore, protease activity
may have had some impact on allergy induction.
Chitinases are widely distributed in living organisms and
are thought to primarily play a role in pathogen defense.
Recently, elevated levels of acid mammalian chitinase were
observed in the lung tissue of asthmatic patients [52],
and exogenous chitinase (Streptomyces griseus) was shown
to activate Protease-activated Receptor-2 in human airway
epithelial cells [53]. Chitinases have been found in M.
anisopliae [41, 54]. Although chitinase activity for both
extracts was elevated compared to the protease (trypsin)
control and the background control, it is not clear from
our current study what impact this may have had on allergy
development.This area merits further examination.
Coexposure to endotoxin is another factor that may
inﬂuence allergic responsiveness. In our study, the M.
anisopliae and HDM extracts had the highest and similar
levels of endotoxin (0.28 EU and 0.27 EU in 80µgo fe x t r a c t
protein) which equate to ∼0.028–0.056 and 0.027–0.054ng
LPS, respectively. This is well below the levels expected to
have an impact on allergic responses [55–58] suggesting that
theendotoxinlevelsin these extractshad littleifany eﬀecton
the response outcome in this study.
Exposure assessment and threshold sensitizing dose are
critical in understanding the development of allergic disease
with regard to a given agent. Studies have found that an
exposure to >2µg Der p 1/g dust is a risk factor for HDM
sensitization in atopic children [59, 60]b u t8 0µg Der group
1allergen/gdustwas requiredtosensitize nonatopicchildren
[61]. Additionally, Arbes et al. [62] estimated that most beds
in US homes have detectable levels of HDM with 2µgH D M
group 1 allergen/g dust in 46.2% ± 2% of beds and 10µg/g
dust in 24.2% ± 2.1% of beds. Even though dust allergen
load and aspiration exposures (as in the current study) are
not equivalent, the fact that there were 1.96µgo fDer group
1allergensin10µgHDMextract proteinsuggeststhatdosing
in our study was within the range of human exposure.
The sensitizing exposure threshold dose like the one
deﬁnedforHDMisnotavailableformostallergensincluding
molds. No exposure studies were found for M. anisopliae.
Dose-response comparisons like the one presented in this
study may provide insight into sensitizing dose thresholds.
The data suggest that Metarhizium anisopliae may be similar
to HDM in allergenic potency. However, it must be noted
that the allergen load in the M. anisopliae extract is
unknown. Furthermore, the HDM extract used in this study
islyophilizedwhole bodies, thatis,notincludingfecal matter
which has a higher concentration of allergens. Therefore, the
allergen load in the HDM extract might be lower than would
be seen in a typical human exposure.
A variety of biopesticides that are available have been
vetted for toxicity and pathogenicity. However, there is
limited data available regarding their allergenicity. One agent
Bacillius thuringiensis, in use formany years, has been shown
to induce IgE responses from occupational exposures [63,
64]. Additionally, there are both human and animal studies
indicating that M. anisopliae exposure may induce allergy
and possibly asthma [32, 33, 35]. Although the data in this
report suggests that M. anisopliae is a robust allergen source,
this is not the case for all molds or fungal biopesticides.
The evaluation of Trichoderma viride,af u n g a lb i o p e s t i c i d e
used to treat seed and soil to inhibit other fungal pathogens,
demonstrated limited capacity to induce allergic responses
compared to HDM in our mouse model (unpublished data).
At this time, human exposure levels and sensitiza-
tion thresholds are unknown for most allergens including
mold/fungal biopesticides. These critical factors must be
considered in evaluating the risk in human allergic dis-
ease development. Importantly, occupational and residential
exposures may increase with an increased use of biological
agents or their products (metabolites, enzymes) as biopes-
ticides. Although human exposure levels are not within
the scope of this paper, the data presented in this study
suggest a threshold dose of M. anisopliae for the induction
of allergic responsiveness which may play a role in asthma
development.
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